Big drug companies are working hard to make cancer treatments called CAR-T cell therapies more accessible. These treatments have been successful but take a long time and are difficult to make. Now, companies like Eli Lilly are buying smaller biotech firms to develop easier-to-use treatments. Eli Lilly recently bought Orna Therapeutics for $2.4 billion. This is part of a trend where big drug companies are investing in treatments that can be made quickly and given to more patients. Current CAR-T treatments involve taking a patient’s cells, changing them in a lab, and putting them back. This process is time-consuming and expensive. New treatments, called off-the-shelf or allogenic therapies, could be ready to use immediately. These treatments face some regulatory challenges, but they hold great promise. Big drug companies hope to use their expertise to make these treatments available to more patients. Eli Lilly, which is new to CAR-T therapies, is using its profits to expand its pipeline. Orna Therapeutics uses a special method to make genetic material more stable. Their lead treatment, ORN-252, is designed for autoimmune diseases like lupus and multiple sclerosis. Lilly aims to overcome the difficulties of current CAR-T therapies with new in vivo treatments. Bristol Myers Squibb (BMS) also bought Orbital for $1.5 billion. Orbital’s lead program targets B cell autoimmune diseases, similar to Lilly’s Orna deal. Kite, a prominent cell therapy company, bought Interius for $350 million. Interius has a promising platform for both cancer and immune system treatments. AbbVie bought Capstan Therapeutics for $2.1 billion. Capstan has an early-stage treatment called CPTX2309 for autoimmune diseases. AbbVie hopes this treatment will be a first-of-its-kind medicine. AstraZeneca bought EsoBiotec for $1 billion. EsoBiotec has a platform that could be used for in vivo cell therapy. AstraZeneca believes this could transform cancer treatments and make them more accessible.